| Immune checkpoint inhibitors for the treatment of bladder cancer A Lopez-Beltran, A Cimadamore, A Blanca, F Massari, N Vau, M Scarpelli, ... Cancers 13 (1), 131, 2021 | 192 | 2021 |
| Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications G Aurilio, A Cimadamore, R Mazzucchelli, A Lopez-Beltran, E Verri, ... Cells 9 (12), 2653, 2020 | 137 | 2020 |
| Variants and new entities of bladder cancer A Lopez‐Beltran, V Henriques, R Montironi, A Cimadamore, ... Histopathology 74 (1), 77-96, 2019 | 136 | 2019 |
| Epigenetic modulations and lineage plasticity in advanced prostate cancer R Ge, Z Wang, R Montironi, Z Jiang, M Cheng, M Santoni, K Huang, ... Annals of Oncology 31 (4), 470-479, 2020 | 132 | 2020 |
| PD-L1 assessment in urothelial carcinoma: a practical approach M Eckstein, A Cimadamore, A Hartmann, A Lopez-Beltran, L Cheng, ... Annals of Translational Medicine 7 (22), 2019 | 100 | 2019 |
| Is there a role for immunotherapy in prostate cancer? A Rizzo, V Mollica, A Cimadamore, M Santoni, M Scarpelli, F Giunchi, ... Cells 9 (9), 2051, 2020 | 82 | 2020 |
| New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen A Cimadamore, M Cheng, M Santoni, A Lopez-Beltran, N Battelli, ... Frontiers in oncology 8, 653, 2018 | 75 | 2018 |
| Immunotherapy in renal cell carcinoma: latest evidence and clinical implications M Santoni, F Massari, V Di Nunno, A Conti, A Cimadamore, M Scarpelli, ... Drugs in Context 7, 2018 | 75 | 2018 |
| Treating prostate cancer by antibody–drug conjugates M Rosellini, M Santoni, V Mollica, A Rizzo, A Cimadamore, M Scarpelli, ... International journal of molecular sciences 22 (4), 1551, 2021 | 67 | 2021 |
| Re: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors M Santoni, F Piva, A Conti, A Santoni, A Cimadamore, M Scarpelli, ... European urology 74 (4), 521-522, 2018 | 55 | 2018 |
| Diagnostic accuracy of novel urinary biomarker tests in non–muscle-invasive bladder cancer: a systematic review and network meta-analysis E Laukhtina, SR Shim, K Mori, DA David, F Soria, P Rajwa, H Mostafaei, ... European urology oncology 4 (6), 927-942, 2021 | 52 | 2021 |
| Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems S Marletta, N Fusco, E Munari, C Luchini, A Cimadamore, M Brunelli, ... Journal of Personalized Medicine 12 (7), 1073, 2022 | 50 | 2022 |
| Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review A Cimadamore, L Cheng, M Scarpelli, F Massari, V Mollica, M Santoni, ... Translational Andrology and Urology 10 (3), 1506, 2021 | 50 | 2021 |
| The identification of immunological biomarkers in kidney cancers A Lopez-Beltran, V Henriques, A Cimadamore, M Santoni, L Cheng, ... Frontiers in Oncology 8, 456, 2018 | 50 | 2018 |
| The role of obesity in renal cell carcinoma patients: clinical-pathological implications G Aurilio, F Piva, M Santoni, A Cimadamore, G Sorgentoni, ... International journal of molecular sciences 20 (22), 5683, 2019 | 49 | 2019 |
| Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype J Rebola, P Aguiar, A Blanca, R Montironi, A Cimadamore, L Cheng, ... Virchows Archiv 475, 445-455, 2019 | 48 | 2019 |
| The human microbiota and prostate cancer: friend or foe? F Massari, V Mollica, V Di Nunno, L Gatto, M Santoni, M Scarpelli, ... Cancers 11 (4), 459, 2019 | 47 | 2019 |
| Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, ... Journal of Clinical Oncology 40 (25), 2913-2923, 2022 | 46 | 2022 |
| RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications O Saeed, A Lopez-Beltran, KW Fisher, M Scarpelli, R Montironi, ... Journal of clinical pathology 72 (2), 135-139, 2019 | 46 | 2019 |
| Morphologic, molecular and clinical features of aggressive variant prostate cancer R Montironi, A Cimadamore, A Lopez-Beltran, M Scarpelli, G Aurilio, ... Cells 9 (5), 1073, 2020 | 43 | 2020 |
Liang Cheng, MDIndiana University School of Medicine, Indianapolis, USA在 iupui.edu 的电子邮件经过验证
Liang Cheng, MDIndiana University School of Medicine, Indianapolis, USA在 iupui.edu 的电子邮件经过验证
Marina ScarpelliProfessore ordinario di Anatomia Patologica在 univpm.it 的电子邮件经过验证